As part of our monthly news service we would like to make you aware of the CML publications of the month. From the many papers published every month Professor Timothy Hughes has selected topical, interesting papers for your perusal that also include an interesting publication on pediatric CML.

Read Professor Hughes' CML publications of the month: October 2024

Clinical CML papers

• Nilotinib versus dasatinib in achieving MR4.5 for de novo CML:
  The randomized JALSG CML212 study
  Matsumura I et al. Blood Adv, Oct 2024 – open access publication
• Tyrosine kinase inhibitor for CML: All the same?
  Veltmaat L & Cortes J. Blood Adv, Oct 2024 – open access publication
• Dose-escalation of second-line and first-line asciminib in chronic myeloid leukemia in chronic-phase:
  The ASC2ESCALATE Phase II trial
  Atallah E et al. Future Oncol, Oct 2024 (epub ahead of print) – open access publication
• Viral infections and incidence of reactivations in chronic myeloid leukemia patients
  Addapt MD et al. Oncology, Oct 2024 (epub ahead of print)
• Treatment-free remission after discontinuation of tyrosine kinase inhibitors in patients with chronic myeloid leukemia in the chronic phase: A systematic review and meta-analysis
  Zheng Z et al. Discov Oncol, Oct 2024 – open access publication
• Asciminib in advanced-line of treatment of CML
  Shacham-Abdulafia A et al. Eur J Haematol, Oct 2024 (epub ahead of print) – open access publication
• Intensification of upfront chemotherapy for patients with myeloid blast crisis in CML: A single centre experience
  Lee BJ et al. Ann Hematol, Oct 2024 (epub ahead of print) – open access publication
• Sudden blast crisis in a CML patient in treatment-free remission: A case report and literature review
  Liang Q et al. Acta Haematol, Oct 2024 (epub ahead of print)

Scientific CML papers

• The BIM deletion polymorphism potentiates the survival of leukemia stem and progenitor cells and impairs response to targeted therapies
  Yu M et al. Leukemia, Oct 2024 (epub ahead of print)
• Computationally driven discovery of a BCR::ABL1 kinase inhibitor with activity in multi-drug resistant CML
  Hill J et al. J Med Chem, Oct 2024 – open access publication

Pediatric papers

• Clinical characteristics and outcomes of CML in adolescents and young adults
  Al Rabi K et al. Clin Lymphoma Myeloma Leuk, Oct 2024